Albumin for Treatment of Ascites in Patients With Cirrhosis

ABSTRACT Ascites is the most common complication of cirrhosis and a major landmark in the transition from compensated to decompensated disease. It is associated with impaired quality of life, frequent hospitalizations, and a high risk of further complications, including spontaneous bacterial peritonitis, hyponatremia, and hepatorenal syndrome (HRS). The rationale for albumin administration in patients with cirrhosis and ascites is primarily based on its role as a plasma expander capable of counteracting effective arterial hypovolemia and circulatory dysfunction, although its non‐oncotic properties may also contribute to its clinical effects. Current international guidelines generally support short‐term albumin administration in three major settings related to ascites: prevention of post‐paracentesis circulatory dysfunction after large‐volume paracentesis, spontaneous bacterial peritonitis, and acute kidney injury (AKI). The optimal use and duration of albumin for plasma expansion in HRS‐AKI are currently highly debated, as new observational data have emerged since publication of the most recent consensus. Emerging evidence also suggests a potential role for albumin in the treatment of hypervolemic hyponatremia in cirrhosis, although data are still limited. Long‐term albumin administration represents a distinct therapeutic strategy aimed at improving ascites control and reducing complications. The ANSWER trial showed clinically relevant benefits in selected patients with uncomplicated ascites, whereas discordant findings from other trials indicate that treatment response may be influenced by patient selection, dose, and duration of therapy. More recently, real‐world studies have provided further insights into the feasibility and outcomes of long‐term albumin administration in specific healthcare settings. Overall, albumin remains an important therapeutic option in the management of patients with cirrhosis and ascites. However, its optimal use depends on a personalized approach that considers the patient's overall status, ongoing complications, potential clinical trajectories, and therapeutic goals.

Authors

Institutions

Publication Details

Journal
Portal hypertension & cirrhosis
Published
2026-11-13
DOI
https://doi.org/10.1002/poh2.70075
Primary Topic
Liver Disease and Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Albumin for Treatment of Ascites in Patients With Cirrhosis

Paolo Caraceni, Maurizio Baldassarre, Giulia Iannone, Giacomo Zaccherini et al.
Portal hypertension & cirrhosis
Liver Disease and Transplantation
article

Albumin for Treatment of Ascites in Patients With Cirrhosis

Paolo Caraceni, Maurizio Baldassarre, Giulia Iannone, Giacomo Zaccherini, Enrico Pompili, Lorenzo Lani, Greta Tedesco
article en

Abstract

ABSTRACT Ascites is the most common complication of cirrhosis and a major landmark in the transition from compensated to decompensated disease. It is associated with impaired quality of life, frequent hospitalizations, and a high risk of further complications, including spontaneous bacterial peritonitis, hyponatremia, and hepatorenal syndrome (HRS). The rationale for albumin administration in patients with cirrhosis and ascites is primarily based on its role as a plasma expander capable of counteracting effective arterial hypovolemia and circulatory dysfunction, although its non‐oncotic properties may also contribute to its clinical effects. Current international guidelines generally support short‐term albumin administration in three major settings related to ascites: prevention of post‐paracentesis circulatory dysfunction after large‐volume paracentesis, spontaneous bacterial peritonitis, and acute kidney injury (AKI). The optimal use and duration of albumin for plasma expansion in HRS‐AKI are currently highly debated, as new observational data have emerged since publication of the most recent consensus. Emerging evidence also suggests a potential role for albumin in the treatment of hypervolemic hyponatremia in cirrhosis, although data are still limited. Long‐term albumin administration represents a distinct therapeutic strategy aimed at improving ascites control and reducing complications. The ANSWER trial showed clinically relevant benefits in selected patients with uncomplicated ascites, whereas discordant findings from other trials indicate that treatment response may be influenced by patient selection, dose, and duration of therapy. More recently, real‐world studies have provided further insights into the feasibility and outcomes of long‐term albumin administration in specific healthcare settings. Overall, albumin remains an important therapeutic option in the management of patients with cirrhosis and ascites. However, its optimal use depends on a personalized approach that considers the patient's overall status, ongoing complications, potential clinical trajectories, and therapeutic goals.

Portal hypertension & cirrhosis
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), University of Bologna (IT)
Good health and well-being
Liver Disease and Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon